RespireRx Pharmaceuticals — Investor Presentation (November 2020)
36 slides from RespireRx Pharmaceuticals's investor presentation, Nov 12, 2020
Slide 1: RespireRx Pharmaceuticals Inc
RespireRx Pharmaceuticals Inc OIGAESRSEL Advanced Wreatinemsito~ Neurological Signaling cs Respiratory Pathways: November 2020
Slide 2: Forward Looking Statements
Forward Looking Statements WN RespireRx eee Inc assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-lo
Slide 3: RespireRx — A Tale of Discovery
RespireRx — A Tale of Discovery WN Resp ireRx “The world is made up of stories Not atoms” Muriel Rukeyser HMS Discovery
Slide 4: Neurons communicate through neurotransmission
* Neurons communicate through a process of neurotransmission in which they release chemical neurotransmitters that bind to specific receptors on adjacent neurons. * RespireRx is developing drugs to modify neurotransmission and create advanced treatments for disorders with high unmet needs.
Slide 5: Corporate Re-Organization
Corporate Re-Organization RespireRx Pharmaceuticals Inc ResolutionRx Pharmaceutical Cannabinoids EndeavourRx Neuromodulators
Slide 6: RespireRx - Organizational Structure
RespireRx - Organizational Structure DB RespireRx al ta Inc T. Jones CEO and President i —_ — | Senior Advisor (tbd) A. Lippa PhD 5 J. Margolis Business ee) Development eee) D. Dickason R. Purcell ; : M. Radin SVP Preclinical SVP Clinical Senior Advisor (tbd) Financial Product Development Product De
Slide 7: RespireRx - Product Development Status
RespireRx - Product Development Status DB RespireRx Pharmaceuticals Inc Preclinical Phase 1 Phase 2 Phase 3 ResolutionRx - Cannabinoids Dronabinol — OSA — a eee Dronabinol Formulation —z7 EndeavourRx - Neuromodulators AMPAkines €X717 - ADHD —— CX1739 - Spinal Cord Injury —————— CX1942 —follow-up com
Slide 8: ResolutionRx
1 Pharmaceuticals Inc HMS Resolution
Slide 9: ResolutionRx - Pharmaceutical Cannabinoids
ResolutionRx - Pharmaceutical Cannabinoids WB RespireRx Peape Inc Dronabinol (49-THC) = Treatment of Obstructive Sleep Apnea (OSA) ® Potential multi-billion $ market — estimated 30 million U.S. patients, with comparable amounts in UK and Germany = Successful Phase 2B clinical trial in OSA = Phase 3
Slide 10: Dronabinol for Obstructive Sleep Apnea
ResolutionRx - Pharmaceutical Cannabinoids HW RespireRx eee Inc Dronabinol for Obstructive Sleep Apnea * Sleep Apnea + Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep + Three types: Obstructive, Central & Mixed * The Sleep Apnea Market i
Slide 11: Dronabinol: A Breakthrough Treatment for OSA
Dronabinol: A Breakthrough Treatment for OSA HA RespireRx eee Inc * Mechanism of Action Dronabinol is A9-THC, a synthetic cannabinoid agonist at CB1 and CB2 receptors * Background Schedule Ill generic drug available by prescription, with a low risk of addiction Approved in 1985 as Marinol” for the t
Slide 12: Two Successful Phase Studies — Phase Ready!
Two Successful Phase 2 Studies — Phase 3 Ready! WN RespireRx o_o Inc ** p<.02, compared to placebo for Phase 2A Phase 2A PACE Phase 2B Placebo 2.5 mg 10 mg Apnea-Hypopnia Index (AHI) p=.02 p=.001 * Double blind, placebo controlled dose-ascending study in patients with OSA, n=19 Two Phase 2 Clinical
Slide 13: A Clinical View of the Pace Trial Results
A Clinical View of the Pace Trial Results NQ RespireRx oem Inc Comments by David Rapoport, MD Professor of Medicine Mount Sinai School of Medicine* “OSA may affect....long term cardiovascular and cerebrovascular health,..... memory loss and progression of Alzheimer Disease biomarkers.” “..dronabinol
Slide 14: EndeavourRx - Neuromodulators
EndeavourRx - Neuromodulators HW RespireRx eee Inc HMS Endeavour 14
Slide 15: Neurons communicate by releasing chemical neurotransmitters
Neurons communicate by releasing chemical neurotransmitters that bind to specific receptors on the adjacent neuron. Glutamate is the major excitatory neurotransmitter and GABA is the major inhibitory neurotransmitter. Neuromodulators do not act directly at the neurotransmitter binding site and have
Slide 16: EndeavourRx - Neuromodulators: Novel Brain Targeting Drugs
EndeavourRx - Neuromodulators DB RespireRx al ta Inc Novel Brain Targeting Drugs Ampakines (AMPA Glutamate Receptor Positive GABAkines (GABA, Receptor Positive Allosteric Modulators) Allosteric Modulators) = 3 Successful phase 2A trials for CX1739 and CX717 " Efficacious in roultiple animal models o
Slide 17: AMPA Glutamate Receptor Structure
AMPA Glutamate Receptor Structure The AMPA receptor is composed of four transmembrane proteins that form a pore, which when activated by glutamate opens and allows positive ions to enter the cell. Ampakine binding sites are located adjacent to the glutamate binding sites and increase the normal exci
Slide 18: Low Impact Ampakines: Targeting Markets with High Unmet Medical Need
Low Impact Ampakines: Targeting Markets with High Unmet Medical Need WN RespireRx . Attention Deficit Hyperactive Disorder (ADHD) — Phase 2B Ready ° Spinal Cord Injury — Phase 2A Ready © Orphan Diseases — Phase 2A Ready 2"4 and 34 Generation Low Impact Ampakines Are Devoid of the Neurotoxicity Obser
Slide 19: Translational Approach: Conduct Clinical Trials
Translational Approach: Conduct Clinical Trials WNQ Resp ireRx Ampakines Reduce Opioid-Induced Respiratory Depression in Average Percent Change from Baseline -30 -40 Phase 2A Clinical Trials CX717 CX1739 Placebo 1500 mg* _— Placebo 900 mg* por | p<.01 * Approximately 15 and 10 mg/kg on a weight basi
Slide 20: Ampakines for the Treatment of ADHD
Ampakines for the Treatment of ADHD WNQ RespireRx eee Inc * Epidemiologic studies of adult | How Much Does It Cost? ADHD have estimated the ASST WIE Be LG Geiss current prevalence to be 4.1% to 4.4% in the US. 1 Average cost of ADHD per « Anestimated 10 million adults person have ADHD. « ADHD in adu
Slide 21: CX717 Shows Significant Improvement in ADHD
CX717 Shows Significant Improvement in ADHD WNQ RespireRx eee Inc OVERALL ADHR-RS HYPERACTIVITY INATTENTIVENESS HIGH DOSE COMPONENT (n=23) - ITT 0 HIGH DOSE COMPONENT (n=23) - ITT Week 1 Week 2 Week 3 0.00 A 0.00 Week 1 Week 2 Week 3 Week 1 Week 2 Week3 200 2 200 400 / 4 ww _ 4.00 7 600 L , a 4 “SN
Slide 22: CX1739 Development Program: Spinal Cord Injury
CX1739 Development Program: Spinal Cord Injury (SCI)* WN RespireRx pespirer Inc * Approximately 288,000 people in US with SCI and 12,500 new cases per year * Treatment costs are prohibitively high and continue for LIFE For example, ~$3.4 Million cost for low tetraplegia injury at 25 years old * <1%
Slide 23: Acute doses of CX717 Improve Motor Neuron Firing
RespireRx Pharmaceuticals Inc Acute doses of CX717 Improve Motor Neuron Firing in Animal Models of Spinal Cord Injury Unilateral hemi-transections at the level of the 24 cervical vertebra are performed on rats and electrical activity is recorded from phrenic nerves, which innervate the diaphragm and
Slide 24: CX717 + Acute Intermittent Hypoxia Improves Motor Neuron Firing
CX717 + Acute Intermittent Hypoxia (IH) vastly Improves Motor Neuron Firing GR RespireRx sjeeaie satin Inc Unilateral hemi-transections at the level of the 24 cervical vertebra are performed on rats and electrical activity is recorded from phrenic nerves, which innervate the diaphragm and contribute
Slide 25: Next Step: Phase Clinical Trial
Next Step: Phase 2 Clinical Trial CX1739 +/- AIH in the Treatment of SCI CX) RespireRx Blinded, Placebo-controlled, Escalating-dose Study of CX1739, With and Without Acute Intermittent Hypoxia (AIH), in Patients with Incomplete Spinal Cord Injury Primary Objectives 1. Evaluate the safety of acute an
Slide 26: GABA Receptor Structure
GABA, Receptor Structure WNQ RespireRx Pharmaceuticals Inc * The GABA, receptor is composed of five GABA, receptor transmembrane proteins that form a pore, which when activated by GABA opens and allows chloride to enter the cell. * GABA, Positive Allosteric Modulators (PAM) binding sites are located
Slide 27: GABA Receptor Heterogeneity
G , Receptor Heterogeneity NQ RespireRx Pharmaceuticals Inc KRM-II-81 is a Selective Potentiator of «2/3-containing GABA, Receptors Tuned to Treat Pharmaco-resistant Epilepsy o 2a mm Valium oc KRMitet an a5 N~ Qo o* ) ae N €a oc N 22 a 2 ge | KRM-II-81 a5 a6 Unlike Valium, KRM-II-81 selectively pote
Slide 28: Pharmaco-Resistant Epilepsy
Pharmaco-Resistant Epilepsy B® RespireRx sive stat Soot Inc * Standard of care agents do not fully control epilepsies and have a variety of side- effect and safety issues including sedation, dizziness, cognitive impairment, and weight gain. * Patients typically take multiple antiepileptic drugs to i
Slide 29: Superior Anti-convulsant Efficacy of KRM-II-81 over Standard of Care
Superior Anti-convulsant Efficacy of KRM-II-81 over Standard of Care WNQ Resp ireRx eee Inc * Broad Anticonvulsant Effects in Animal Models * -9 acute rodent models * -2chronic rodent models * -3 pharmaco-resistant models * - 2 anti-epileptogenic models - unlike many anticonvulsants * - Better than
Slide 30: Translational Results Predict Human Efficacy
Translational Results Predict Human Efficacy WNQ RespireRx KRM-II-81 Reduces Epileptiform Activity in Cortical Slices from Juvenile Epileptic Patients Patient 001 Patient 002 0.15 ahi © Control land MBbhas Abdaseiiild, 0 10 20 30 ° 10 20 30 40 50 60 Channel Firing Rate Hz ° Pal i=) & Es op oe O44 =<
Slide 31: Chronic Pain - Neuropathic and Inflammatory
Chronic Pain - Neuropathic and Inflammatory WN RespireRx sive stat Soot Inc * Unmet need * Opioid limitations — respiratory depression, tolerance, addiction, abuse, side effects such as sedation * GABAergic drugs such as GABApentin and Neurontin — limited efficacy, side effects, dysphoria, partial t
Slide 32: Pharmacological Properties of KRM-II-81
Pharmacological Properties of KRM-II-81 WNQ RespireRx Peep ee Inc * Broad anticonvulsant effects in animal models of epilepsy ¢ Broad analgesic effects in animal models of neuropathic and inflammatory pain * Lack of Tolerance * Reduced sedation and motor impairment enabling higher doses to achieve t
Slide 33: RespireRx - Summary of Assets
RespireRx - Summary of Assets WN Resp ireRx HMS Discovery 33
Slide 34: A Wealth of Potential Products
A Wealth of Potential Products Pharmaceutical Cannabinoids Dronabinol (49-THC) Treatment of Obstructive Sleep Apnea (OSA) Potential multi-billion § market — estimated 30 million U.S. patients, with comparable amounts in UK and Germany Successful Phase 2B clinical trial in OSA Phase 3 ready, pending
Slide 35: RespireRx - Summary of Assets
RespireRx - Summary of Assets BW RespireRx sjeeaie satin Inc * Highly desirable assets — advancing clinical programs and IP * World Class Management Team and Board of Directors * Expanding portfolio of novel products across multiple therapeutic categories and indications * Broad flexibility in model
Slide 36: RespireRx Pharmaceuticals Inc
RespireRx Pharmaceuticals Inc OG QE-TRSPL Jeti jpoatenniexo)
RespireRx Pharmaceuticals — Investor Presentation (November 2020) on 6ix